At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Percutaneous coronary intervention (PCI) (procedure), Measurement of the angina threshold (diagnostic test)
- How long the study runs
- Study runs about 34 months (dates as stated)
- About the drug or intervention
- Percutaneous coronary intervention (PCI) — procedure: Clinically indicated PCI for the management of stable angina · Measurement of the angina threshold — diagnostic test: Following stenting, the order in which to perform the angina threshold assessment at the location of each stent will be randomised.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 60
- Started
- 2026-02-10
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for angina (stable)
- • NA - 60 participants
- • ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with angina (stable)
Where?
- • Basildon - Mid and South Essex NHS Foundation Trust
- • Bournemouth - University Hospitals Dorset NHS Foundation Trust
- • London - Chelsea and Westminster Hospital NHS Foundation Trust
- • London - Guy's and St Thomas' NHS Foundation Trust
- • +3 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Eligibility for PCI due to angina or angina-equivalent symptoms on exertion
- ✓2 severe epicardial stenoses in a major coronary artery, defined as:
- ✓≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)
- ✓Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA
- ✓Evidence of ischaemia on an invasive or non-invasive test, including:
Who cannot take part
- ✗Age \<18 years
- ✗Acute coronary syndrome within 3 months
- ✗Previous coronary artery bypass graft
- ✗Significant left main stem disease
- ✗Single lesion amenable to PCI
See the full criteria
Where Is This Study? (7 UK sites)
Mid and South Essex NHS Foundation Trust
Basildon, United Kingdom
University Hospitals Dorset NHS Foundation Trust
Bournemouth, United Kingdom
Chelsea and Westminster Hospital NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
St George's University Hospitals NHS Foundation Trust
London, United Kingdom
How to Get in Touch
Kayla Chiew, MBBS MRCP
Sponsor contactCONTACT
Rasha Al-Lamee, MBBS PhD MRCP
Sponsor contactCONTACT
